Struggling with PCI after TAVI? This session breaks it down with 3 real-world cases. You'll learn when and how to perform revascularization in severe AS patients, the impact of commissure alignment on future coronary access, and expert techniques for post-TAVI PCI:

• Case 1: Managing a patient with...

Should you intervene earlier in patients with moderate aortic stenosis and heart failure? This session breaks down the latest trials shaping clinical decisions.

You'll get the key takeaways from EARLY TAVR, EVOLVED, TAVR UNLOAD, PROGRESS and EXPAND TAVR II (what they reveal, what they don’t and how...

This comprehensive session delves into the 'burning issues' in TAVI, covering a wide range of topics. Discover the impact of catheter insertion on left ventricular pacing, the importance of the en-face view for coronary cannulation, comparisons of TAVI valve expansions, indications for left and right ventricular...

The COVID-19 pandemic caused huge disruption to healthcare services and dramatically reduced hospital admissions for MI.1 In response, the We CARE initiative was created from a collaboration between PCR and Stent – Save a Life! to rebuild patient confidence in pursuing timely medical treatment and to help...

The aims of We CARE are to rebuild patient confidence and help stakeholders provide effective and timely cardiac care through knowledge, education and training.

Paris, France. Since the start of the COVID-19 pandemic, patients have been consistently deprived of timely cardiovascular treatment. This is due in part to measures taken in response to the sanitary crisis, but it is also due to patients' own unwillingness to seek medical help, even...

A genotype-guided oral P2Y12 inhibitor strategy compared with conventional clopidogrel therapy with point-of-care genotyping in CYP2C19 LOF patients with ACS and stable CAD undergoing PCI resulted in a no significant reduction in ischemic events at 12-months.

At TCT Connect 2020, Damien Collison presented the results of the TARGET FFR trial. Carlos Collet provides a summary of the key messages.

Quantitative coronary angiography-guidance versus intravascular ultrasound-guidance for drug-eluting stent implantation (GUIDE-DES trial): A multicenter, non-inferiority, randomised-controlled trial

Nicola Ryan provides her take on the final results of GUIDE-DES which were presented by Taeoh Kim during the ESC 2023 congress in Amsterdam.

Note the assumptions in this article are based on the presentation...

Nicola Ryan provides her take on the FULL REVASC trial which was presented at ACC.24 in Atlanta and published Simultaneously in NEJM.

The FULL REVASC trial is a multicentre registry-based randomised control trial comparing FFR-guided complete revascularisation of non-culprit lesions versus culprit lesion PCI alone in patients presenting...

Mirvat Alasnag provides her take on the CLEAR SYNERGY trial presented by Sanjit S Jolly at AHA 2024 in Chicago.

Nicola Ryan provides her take on the results of TAILORED-CHIP presented by Duk-Woo Park at the ESC Congress 2025 in Madrid.

Nicola Ryan provides her take on this clinical trial presented by Lisa Mielniczuk at the American College of Cardiology Scientific Session (ACC.23/WCC) – note this analysis is based upon the presented slides alone.

Chiara De Biase provides her take on the results of AQUATIC presented by Martine Gilard at ESC Congress 2025 in Madrid.

Mirvat Alasnag provides her take on OPTION-STEMI, presented by Youngkeun Ahn at ESC Congress 2025 in Madrid.

Authored by Hector Garcia-Garcia and Jorge Sanz-Sanchez, this article examines pivotal randomized clinical trials on drug-coated balloons in coronary artery disease. It highlights their role in managing in-stent restenosis, de novo small vessel lesions, and large vessel lesions while exploring future directions through ongoing trials.